Article Correctness Is Author's Responsibility: Study supports effectiveness of new fast-acting antidepressant, esketamine nasal spray

(American Psychiatric Association) New research supports the effectiveness and safety of esketamine nasal spray in treating depression in people who have not responded to previous treatment. The research will be published online today in the American Journal of Psychiatry. This study is one of the key studies that led to the recent Food and Drug Administration (FDA) approval of esketamine nasal spray, in conjunction with an oral antidepressant, for use in people with treatment-resistant depression.